CSPC PHARMA (01093.HK) -0.180 (-2.419%) Short selling $117.62M; Ratio 20.387% announced that the Groups self-developed ustekinumab injection, marketed under the brand name Enyike, has been approved for market launch by the National Medical Products Administration.The originator drug Stelara (ustekinumab injection) was approved for launch in China in 2017 and has been approved in China for three indications: adult plaque psoriasis, pediatric plaque psoriasis and Crohns disease. (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-26 16:25.)Related News UBS Upgrades CSPC PHARMA (01093.HK) to Buy, Says Valuation Yet to Reflect AI Drug R&D Strength
AASTOCKS Financial News